Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28509852
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
#MMPMID28509852
Maselli DJ
; Keyt H
; Restrepo MI
Int J Mol Sci
2017[May]; 18
(5
): ? PMID28509852
show ga
The management of patients with chronic respiratory diseases affected by
difficult to treat infections has become a challenge in clinical practice.
Conditions such as cystic fibrosis (CF) and non-CF bronchiectasis require
extensive treatment strategies to deal with multidrug resistant pathogens that
include Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus,
Burkholderia species and non-tuberculous Mycobacteria (NTM). These challenges
prompted scientists to deliver antimicrobial agents through the pulmonary system
by using inhaled, aerosolized or nebulized antibiotics. Subsequent research
advances focused on the development of antibiotic agents able to achieve high
tissue concentrations capable of reducing the bacterial load of
difficult-to-treat organisms in hosts with chronic respiratory conditions. In
this review, we focus on the evidence regarding the use of antibiotic therapies
administered through the respiratory system via inhalation, nebulization or
aerosolization, specifically in patients with chronic respiratory diseases that
include CF, non-CF bronchiectasis and NTM. However, further research is required
to address the potential benefits, mechanisms of action and applications of
inhaled antibiotics for the management of difficult-to-treat infections in
patients with chronic respiratory diseases.
free
free
free
